^
Association details:
| Biomarker: | FGFR1 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Published date:
08/05/2023
Excerpt:
We recruited patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1-4 alterations...an objective response was observed in 64 (30% [95% CI 24-36]) of 217 patients across 16 distinct tumour types... RAGNAR results show clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options.
DOI:
10.1016/S1470-2045(23)00275-9
Trial ID:
Source:
Title:
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
Published date:
05/25/2023
Excerpt:
Primary analysis results from RAGNAR, the largest tumor agnostic trial of targeted tx to date, confirm efficacy of erda in heavily pretreated pts with FGFRalt advanced solid tumors. Erda activity was observed in adults and adolescents across tumor types, and across FGFR1-3 gene mutations and fusions.
DOI:
10.1200/JCO.2023.41.16_suppl.3121
Trial ID:
